Breakthrough EU approval for Dupixent offers new hope for children with eosinophilic esophagitis
The European Medicines Agency (EMA) has granted approval for Dupixent, a therapy developed by Sanofi and Regeneron, to treat eosinophilic esophagitis (EoE) in children as ... Read More
Eupraxia Pharmaceuticals announces promising results for EP-104GI in eosinophilic esophagitis trial
Eupraxia Pharmaceuticals Inc., listed on both TSX and NASDAQ under the ticker EPRX, has revealed encouraging results from its ongoing Phase 1b/2a RESOLVE trial. The ... Read More
Sanofi, Regeneron get Dupixent EC approval for eosinophilic esophagitis
French pharmaceutical company Sanofi and Regeneron, an American biotechnology company, have received the approval of the European Commission (EC) to market their Dupixent (dupilumab) injection ... Read More
FDA refuses to approve AstraZeneca’s sBLA for Fasenra in CRSwNP
The US Food and Drug Administration (FDA) has refused to approve the supplemental biologics license application (sBLA) of AstraZeneca’s asthma drug Fasenra (benralizumab) for the ... Read More
Dupixent delivers positive results in eosinophilic esophagitis trial
Regeneron Pharmaceuticals and Sanofi said that their co-developed eczema drug Dupixent (dupilumab) has met the co-primary endpoints of Part A of a phase 3 trial ... Read More